PDX model details
| PDX ID |
365R |
| Host Strain(and Source) |
NSG
Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Renal |
Current Generation
(* indicates number of generations grown in Castrate host) |
8 |
| Average PDX Generation Time (days +/- SEM) |
224 ± 25 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
365R |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
N |
| ERG |
Y |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 365R |
CCND1 |
1.995 |
7.970 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
USP28 |
0.585 |
3.000 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
KMT2A |
0.585 |
3.000 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
CDK12 |
0.597 |
3.025 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
SPOP |
0.546 |
2.920 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
AXIN2 |
0.546 |
2.920 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
MYC |
0.579 |
2.988 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
PTEN |
-14.453 |
8.920e-05 |
Homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
PTEN |
-1.752 |
0.594 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
SUFU |
-1.752 |
0.594 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
CDH1 |
-0.938 |
1.044 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
ZFHX3 |
-0.938 |
1.044 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
FANCA |
-0.938 |
1.044 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
PRPF8 |
-0.927 |
1.052 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
TP53 |
-0.927 |
1.052 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
NCOR1 |
-0.927 |
1.052 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
ZNRF3 |
-0.929 |
1.050 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 365R |
IGF2R |
-0.953 |
1.033 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
365R |
| Sample Site |
Prostate |
| Sample source |
Radical prostatectomy |
| Pathology Tumour Diagnosis |
None |
| Gleason Score |
9 |
| Primary Gleason Score |
4 |
| Secondary Gleason Score |
5 |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
5 |
| Tumour Grade |
pT3aN1 |
| D'Amico Risk Classification |
7 |
| Tumour Volume (in cc) |
8.6 |
| Treatment Prior to Specimen Collection |
None |
| |
|
Patient Information
| Patient Number |
365 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
6.3 |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download Plot
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Total Read Depth
|
Alternate Frequency
|
Consequence
|
Exon
|
GnomAD AF
|
CADD PHRED score
|
ClinVar significance
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 365R |
TP53 |
235 |
1.0 |
Stop gained |
'10/11 |
. |
36 |
Pathogenic
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 365R |
PRDM2 |
465 |
0.53 |
Missense variant |
'8/10 |
. |
27.4 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 365R |
NR3C1 |
594 |
0.52 |
Stop gained |
'2/9 |
. |
36 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 365R |
CACNA1H |
571 |
0.48 |
Missense variant |
'17/35 |
0.0007575 |
3.993 |
Likely benign
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 365R |
SDHA |
408 |
0.47 |
Missense variant |
'2/15 |
0.0004432 |
22.9 |
Conflicting interpretations of pathogenicity
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 365R |
RYR1 |
703 |
0.4 |
Missense variant |
'43/106 |
0.0004264 |
22.5 |
Conflicting interpretations of pathogenicity
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 365R |
ASPM |
609 |
0.39 |
Stop gained |
'18/28 |
2.04E-05 |
38 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
No information in Drug dosing Table
